Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study

Shots: The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos. The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides, ANGPTL3, apoC-III, VLDL-C, non-HDL cholesterol, no reduction in liver fat and is well tolerated AKCEA-ANGPTL3-LRx is […]Read More

Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for

Shots: Akcea and Ionis to receive $250M, up to $1.3B as development, regulatory and commercial milestone with royalties on global sales of AKCEA-ANGPTL3-L(Rx) splitting equally b/w the companies. Akcea will settle its $125M obligations to Ionis in Akcea common stock Pfizer will be responsible for all development and regulatory activities and costs after P-II study. […]Read More